Globus Medical Receives $104.36 Average Target Price from Analysts

Shares of the medical device company have a 'Moderate Buy' consensus rating from 16 firms.

Apr. 14, 2026 at 11:54am

Got story updates? Submit your updates here. ›

A dramatic black and white close-up photograph of the internal components of a high-tech medical device, conveying the precision and complexity of Globus Medical's engineering.The advanced engineering and manufacturing capabilities that power Globus Medical's innovative medical devices.Audubon Today

Shares of Globus Medical, Inc. (NYSE:GMED) have been given a consensus recommendation of 'Moderate Buy' by 16 ratings firms covering the company. The average 12-month price target among brokerages that have covered the stock in the last year is $104.36.

Why it matters

This report indicates that Wall Street analysts are generally bullish on Globus Medical's prospects, with a majority recommending investors buy the stock. The company's strong performance and growth potential in the medical device market for spine and orthopedic applications are likely driving this positive sentiment.

The details

The 16 ratings firms covering Globus Medical have issued a mix of ratings, including 5 hold, 8 buy, and 3 strong buy recommendations. Several analysts have recently raised their price targets on the stock, with Piper Sandler setting a $115 target and TD Cowen upgrading the company to a 'strong-buy' rating.

  • Globus Medical reported Q4 2025 earnings on February 24, 2026.

The players

Globus Medical, Inc.

A leading medical device company specializing in musculoskeletal solutions for spine and orthopedic applications, headquartered in Audubon, Pennsylvania.

David C. Paul

The founder and chairman of Globus Medical.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Globus Medical's upcoming earnings report and any further analyst commentary on the company's growth prospects and valuation.

The takeaway

Globus Medical's strong performance and positive analyst sentiment reflect the company's leadership position in the growing medical device market for spine and orthopedic treatments. As the company continues to innovate and expand its product portfolio, it appears poised for continued success.